Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis

Current Cancer Drug Targets

Volumn 14, Issue 6, 2014, Pages 557-566

  Yang, Meng Hang ^a   Zang, Yuan Sheng ^a   Huang, Hai ^a   Chen, Kun ^a   Li, Bing ^a   Sun, Guang Yuan ^a   Zhao, Xue Wei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Arsenic trioxide; Dll4; HIF 1 ; Lung cancer; Notch 1; VEGF; VEGFR 2

Indexed keywords

ARSENIC TRIOXIDE; KI 67 ANTIGEN; SORAFENIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; DLL4 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; ORGANOARSENIC DERIVATIVE; OXIDE; SIGNAL PEPTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN; CARRIER PROTEINS AND BINDING PROTEINS; DELTA LIKE LIGAND 4 PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MALE; MICROSCOPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; TIME; TUMOR CELL LINE; VASCULARIZATION; ELECTRON MICROSCOPY; NON SMALL CELL LUNG CANCER; SMALL CELL LUNG CANCER;

ANGIOGENESIS INHIBITORS; ANIMALS; ARSENICALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OXIDES; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907357013     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140725090000     Document Type: Article

References (48)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin., 2011, 61 (2), 69-90.
2. Weis, S.M.; Cheresh, D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med., 2011, 17 (11), 1359-1370.
3. Takahashi, S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol. Pharm. Bull., 2011, 34 (12), 1785-1788.
4. Ebos, J.M.; Kerbel, R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol., 2011, 8 (4), 210-221.
5. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature, 2005, 438 (7070), 967-974.
6. Cooney, M.M.; van Heeckeren, W.; Bhakta, S.; Ortiz, J.; Remick, S.C. Drug insight: vascular disrupting agents and angiogenesisnovel approaches for drug delivery. Nat. Clin. Pract. Oncol., 2006, 3 (12), 682-692.
7. Chen, S.J.; Zhou, G.B.; Zhang, X.W.; Mao, J.H.; de The, H.; Chen, Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 2011, 117 (24), 6425-6437.
8. Waxman, S.; Anderson, K.C. History of the development of arsenic derivatives in cancer therapy. Oncologist, 2001, 6 (Suppl 2), 3-10.
9. Ma, Y.; Wang, J.; Liu, L.; Zhu, H.; Chen, X.; Pan, S.; Sun, X.; Jiang, H. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor- κB. Cancer Lett., 2011, 301 (1), 75-84.
10. Xia, J.; Li, Y.; Yang, Q.; Mei, C.; Chen, Z.; Bao, B.; Ahmad, A.; Miele, L.; Sarkar F.H.; Wang, Z. arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer. Int. J. Mol. Sci., 2012, 13 (8), 9627-9641.
11. Yuan, Z.; Wang, F.; Zhao, Z.; Zhao, X.; Qiu, J.; Nie, C.; Wei, Y. BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells. PLoS One, 2011, 6(5), e20586.
12. Beauchamp, E.M.; Ringer, L.; Bulut, G.; Sajwan, K.P.; Hall, M. D.; Lee, Y.C.; Peaceman, D.; Ozdemirli, M.; Rodriguez, O.; Macdonald, T.J.; Albanese, C.; Toretsky, J.A.; Uren A. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J. Clin. Invest., 2011; 121 (1), 148-160.
13. Guo, W.; Tang, X.D.; Tang, S.; Yang, Y. Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma. Zhonghua Wai Ke Za Zhi, 2006, 44 (12), 805-808.
14. Li, H.; Zhu, X.; Zhang, Y.; Xiang, J.; Chen, H. Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction. J. Exp. Clin. Cancer Res., 2009, 28 (1), 110.
15. Chien, C.W.; Yao, J.H.; Chang, S.Y.; Lee, P.C.; Lee, T.C. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide. Toxicol. Appl. Pharmacol., 2011, 257 (1), 59-66.
16. Jin, H.O.; Yoon, S.I.; Seo, S.K.; Lee, H.C.; Woo, S.H.; Yoo, D.H.; Lee, S.J.; Choe, T.B.; An, S.K.; Kown, T.J.; Kim, J.; Park, M.J.; Hong, S.; Park, I.C.; Rhee, C.H. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem. Pharmacol., 2006, 72 (10), 1228-1236.
17. Liu, B.; Pan, S.; Dong, X.; Qiao, H.; Jiang, H.; Krissansen, G.W.; Sun, X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci., 2006, 97 (7), 675-681.
18. Park, W.H.; Seol, J.G.; Kim, E.S.; Hyun, J.M.; Jung, C.W.; Lee, C.C.; Kim, B.K.; Lee, Y.Y. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res., 2000, 60 (11), 3065-3071.
19. Zhang, X.; Jia, S.; Yang, S.; Yang, Y.; Yang, T.; Yang, Y. Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression. J. Cell Biochem., 2012, 113 (11), 3528-3535.
20. Cai, X.; Shen, Y.L.; Zhu, Q.; Jia, P.M.; Yu, Y.; Zhou L.; Huang, Y.; Zhang, J.; Xiong, S.; Chen, S.; Wang, Z.; Chen, Z.; Chen, G. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia, 2000, 14, 262-270.
21. Miller, W.H. Molecular targets of arsenic trioxide in malignant cells. Oncologist, 2002, 7 Suppl 1, 14-19.
22. Estan, M.C.; Calvino, E.; de Blas, E.; Boyano-Adanez, M.D.C.; Mena, M.L.; Gomez-Gomez, M.; Rial, E.; Aller, P. 2-Deoxy-Dglucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways. Biochem. Pharmacol., 2012, 84 (12), 1604-1616.
23. Wang, X.; Wang, G.; Dong, D.; Fu, S.; Yang, B. Inhibition on LS- 174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide. Exp. Toxicol. Pathol., 2008, 60 (6), 481-488.
24. Zhou, C.; Boggess, J.F.; Bae-Jump, V.; Gehrig, P.A. Induction of apoptosis and inhibition of telomerase activity by arsenic trioxide (As2O3) in endometrial carcinoma cells. Gynecol. Oncol., 2007, 105 (1), 218-222.
25. Li, H.C.; Wang, C.X.; Huang, C.; Wang, L.F.; Mu, X.Y.; Jiang, S. J. Effect and mechanism of arsenic trioxide on chemosensitivity of human lung adenocarcinoma cells. Zhonghua Jie He He Hu Xi Za Zhi, 2003, 26 (11), 689-692.
26. Tan, X.M.; Xiu, Q.Y.; Li, B. Intracavitary administration of arsenic trioxide in treatment of lung cancer complicated with pleural effusion. Acad. J. Second Mil. Med. Univ., 2009, 30 (7), 866-8. [Article in Chinese] http://www.ajsmmu.cn/ajsmmu/ch/reader/view_abstract.aspx?file_no=20081053&flag=1
27. Qu, G.P.; Xiu, Q.Y.; Li, B.; Liu, Y.A.; Zhang, L.Z. Arsenic trioxide inhibits the growth of human lung cancer cell lines via cell cycle arrest and induction of apoptosis at both normoxia and hypoxia. Toxicol. Ind. Health, 2009, 25 (8), 505-515.
28. Xiao, Y.F.; Liu, S.X.; Wu, D.D.; Chen, X.; Ren, L. F. Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. World J. Gastroenterol., 2006, 12 (36), 5780-5786.
29. Xiao, Y.F.; Wu, D.D.; Liu, S.X.; Chen, X.; Ren, L.F. Effect of arsenic trioxide on vascular endothelial cell proliferation and expression of vascular endothelial growth factor receptors Flt-1 and KDR in gastric cancer in nude mice. World J. Gastroenterol., 2007, 13 (48), 6498-6505.
30. Shen, Z.Y.; Shen, J.; Chen, M.H.; Wu, X.Y.; Wu, M.H.; Zeng, Y. The inhibition of growth and angiogenesis in heterotransplanted esophageal carcinoma via intratumoral injection of arsenic trioxide. Oncol. Rep., 2003, 10 (6), 1869-1874.
31. Jakobsen, J.N.; Sorensen, J.B. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer, 2013, 79 (1), 1-7.
32. Gridelli, C.; Rossi, A.; Maione, P.; Rossi, E.; Castaldo, V.; Sacco, P.C.; Colantuoni, G. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist, 2009, 14 (6), 612-620.
33. Wheatley-Price, P.; Shepherd, F.A. Targeting angiogenesis in the treatment of lung cancer. J. Thorac. Oncol., 2008, 3 (10), 1173-1184.
34. Scagliotti, G.; Govindan, R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of nonsmall cell lung cancer. Oncologist, 2010, 15 (5), 436-446.
35. Horn, L; Sandler, A.B. Angiogenesis in the treatment of non-small cell lung cancer. Proc. Am. Thorac. Soc., 2009, 6 (2), 206-217.
36. Kao, Y.H.; Yu, C.L.; Chang, L.W.; Yu, H.S. Low concentrations of arsenic induce vascular endothelial growth factor and nitric oxide release and stimulate angiogenesis in vitro. Chem. Res. Toxicol., 2003, 16 (4), 460-468.
37. Soucy, N.V.; Ihnat, M.A.; Kamat C.D.; Hess, L.; Post, M.J.; Klei, L.R.; Clark, C.; Barchowsky, A. Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol Sci., 2003, 76 (2), 271-279.
38. Roboz, G.J.; Dias, S.; Lam, G.; Lane, W.J.; Soignet, S.L.; Warrell, R.P.; Rafii, S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood, 2000, 96 (4), 1525-1530.
39. Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature, 2011, 473(7347), 298-307.
40. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med., 2008, 358, 2039-2049.
41. Yan, M.; Plowman, G.D. Delta-like 4/Notch signaling and its therapeutic implications. Clin. Cancer Res., 2007, 13, 7243-7246.
42. Kume, T. Novel insights into the differential functions of Notch ligands in vascular formation. J. Angiogenes. Res., 2009, 1, 8-16.
43. Kuhnert, F.; Kirshner, J.R.; Thurston, G. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc. Cell., 2011, 3, 20-27.
44. Noguera-Troise, I.; Daly, C.; Papadopoulos, N.J.; Coetzee, S.; Boland, P.; Gale, N.W.; Lin, H.C.; Yancopoulos, G.D.; Thurston, G. Blockade of Dll4 inhibits tumour growth by promoting nonproductive angiogenesis. Nature, 2006, 444, 1032-1037.
45. Scehnet, J.S.; Jiang, W.; Kumar, S.R.; Krasnoperov, V.; Trindade, A.; Benedito, R.; Djokovic, D.; Borges, C.; Ley, E.J.; Duarte, A.; Gill, P.S. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood, 2007, 109 (11), 4753-4760.
46. Reznikova, T.V.; Phillips, M.A.; Rice, R.H. Arsenite suppresses Notch1 signaling in human keratinocytes. J. Invest. Dermatol., 2009, 129, 155-161.
47. Zhen, Y.; Zhao, S.; Li, Q.; Li, Y.; Kawamoto, K. Arsenic trioxidemediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett., 2010, 292, 64-72.
48. Shen, Z.X.; Chen, G.Q.; Ni, J.H.; Li, X.S.; Xiong, S.M.; Qiu, Q. Y.; Zhu, J.; Tang, W.; Sun, G.L.; Yang, K.Q.; Chen, Y.; Zhou, L.; Fang, Z.W.; Wang, Y.T.; Ma, J.; Zhang, P.; Zhang, T.D.; Chen, S. J.; Chen, Z.; Wang, Z.Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89 (9), 3354-3360.